C-Myc modulation and acetylation is a key HDAC inhibitor target in cancer

A. Nebbioso; V. Carafa; M. Conte; F.P. Tambaro; A. Ciro; J. Martens; M. Nees; R. Benedetti; I. Pallavicini; S. Minucci; G. Garcia-Manero; F. Iovino; G. Lania; C. Ingenito; V.B. Petrizzi; H.G. Stunnenberg; L. Altucci

doi:10.1158/1078-0432.CCR-15-2388

C-Myc modulation and acetylation is a key HDAC inhibitor target in cancer

A. Nebbioso, V. Carafa, M. Conte, F.P. Tambaro, A. Ciro, J. Martens, M. Nees, R. Benedetti, I. Pallavicini, S. Minucci, G. Garcia-Manero, F. Iovino, G. Lania, C. Ingenito, V.B. Petrizzi, H.G. Stunnenberg, L. Altucci

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	2542-2555
Number of pages	14
Journal	Clinical Cancer Research
Volume	23
Issue number	10
DOIs	https://doi.org/10.1158/1078-0432.CCR-15-2388
Publication status	Published - 2017

Access to Document

10.1158/1078-0432.CCR-15-2388

https://www.scopus.com/inward/record.uri?eid=2-s2.0-84995889486&doi=10.1158%2f1078-0432.CCR-15-2388&partnerID=40&md5=9e5711fef2dc634e228d016a1b5cc03a

Cite this

Nebbioso, A., Carafa, V., Conte, M., Tambaro, F. P., Ciro, A., Martens, J., Nees, M., Benedetti, R., Pallavicini, I., Minucci, S., Garcia-Manero, G., Iovino, F., Lania, G., Ingenito, C., Petrizzi, V. B., Stunnenberg, H. G., & Altucci, L. (2017). C-Myc modulation and acetylation is a key HDAC inhibitor target in cancer. Clinical Cancer Research, 23(10), 2542-2555. https://doi.org/10.1158/1078-0432.CCR-15-2388

Nebbioso, A, Carafa, V, Conte, M, Tambaro, FP, Ciro, A, Martens, J, Nees, M, Benedetti, R, Pallavicini, I , Minucci, S, Garcia-Manero, G, Iovino, F, Lania, G, Ingenito, C, Petrizzi, VB, Stunnenberg, HG & Altucci, L 2017, 'C-Myc modulation and acetylation is a key HDAC inhibitor target in cancer', Clinical Cancer Research, vol. 23, no. 10, pp. 2542-2555. https://doi.org/10.1158/1078-0432.CCR-15-2388

@article{4a5c9827e9da4be196009cbe16de9f99,

title = "C-Myc modulation and acetylation is a key HDAC inhibitor target in cancer",

author = "A. Nebbioso and V. Carafa and M. Conte and F.P. Tambaro and A. Ciro and J. Martens and M. Nees and R. Benedetti and I. Pallavicini and S. Minucci and G. Garcia-Manero and F. Iovino and G. Lania and C. Ingenito and V.B. Petrizzi and H.G. Stunnenberg and L. Altucci",

note = "Cited By :4 Export Date: 6 March 2018",

year = "2017",

doi = "10.1158/1078-0432.CCR-15-2388",

language = "English",

volume = "23",

pages = "2542--2555",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "10",

}

TY - JOUR

T1 - C-Myc modulation and acetylation is a key HDAC inhibitor target in cancer

AU - Nebbioso, A.

AU - Carafa, V.

AU - Conte, M.

AU - Tambaro, F.P.

AU - Ciro, A.

AU - Martens, J.

AU - Nees, M.

AU - Benedetti, R.

AU - Pallavicini, I.

AU - Minucci, S.

AU - Garcia-Manero, G.

AU - Iovino, F.

AU - Lania, G.

AU - Ingenito, C.

AU - Petrizzi, V.B.

AU - Stunnenberg, H.G.

AU - Altucci, L.

N1 - Cited By :4 Export Date: 6 March 2018

PY - 2017

Y1 - 2017

U2 - 10.1158/1078-0432.CCR-15-2388

DO - 10.1158/1078-0432.CCR-15-2388

M3 - Article

VL - 23

SP - 2542

EP - 2555

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -